Back

Impact of P-glycoprotein and/or CYP3A4-interacting drugs on the risk-benefit profile of NOACs in patients with atrial fibrillation: a meta-analysis

4 April 2022 (13:00 - 13:30)
Organised by:
Congress Presentation Part of: Moderated ePosters - How to optimise stroke prevention in atrial fibrillation Oral Anticoagulation EHRA Premium Access EHRA 2022

About the speaker

Photo
Mr Maxim Grymonprez

University Hospital Ghent, Gent (Belgium)

3 More presentations in this session

Presentation thumbnail
One-year results from the FLXibility post-approval study: final real-world clinical outcomes with a next-generation left atrial appendage closure device
Professor T. Betts (Oxford, GB)
Abstract Slides
Presentation thumbnail
Prevalence and outcomes of hypoattenuation defects and appendage patency on computed tomography after left atrial appendage closure
Professor H. Cochet (Bordeaux, FR)
Abstract Slides
Presentation thumbnail
Single versus dual antiplatelet therapy following transcatheter left atrial appendage closure
Doctor A. Sabbag (Ramat Gan, IL)

Access the full session

Session thumbnail
Moderated ePosters - How to optimise stroke prevention in atrial fibrillation

The Event

Event poster

EHRA 2022

4 April 2022 13:00 CET
You may be interested in
thumbnail
Congress Session
Stroke prevention in clinical and subclinical atrial fibrillation
thumbnail
Congress Presentation
State-of-the-art lecture on stroke and bleeding risk in atrial fibrillation: walking the tight rope
thumbnail
Congress Session
Oral anticoagulation in subclinical atrial fibrillation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources